N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in yersinia: Novel antivirulence agents

Journal of Medicinal Chemistry

Volumn 52, Issue 18, 2009, Pages 5626-5634

  Kim, Oak K ^a   Garrity Ryan, Lynne K ^a   Bartlett, Victoria J ^a,b   Grier, Mark C ^a   Verma, Atul K ^a   Medjanis, Gabriel ^a   Donatelli, Janice E ^a   Macone, Ann B ^a   Tanaka, S Ken ^a   Levy, Stuart B ^a   Alekshun, Michael N ^a,c  

^a Transcept Pharmaceuticals Inc   (United States)

^b PFIZER INC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 FLUOROPHENYL) N [4 (1 HYDROXY 5 METHYL 6 NITRO 1H BENZOIMIDAZOL 2 YL)PHENYL]ACRYLAMIDE; 3 (4 FLUOROPHENYL) N [4 (1 HYDROXY 6 NITRO 1H BENZOIMIDAZOL 2 YL)PHENYL]ACRYLAMIDE; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; BENZIMIDAZOLE DERIVATIVE; N [4 (1 HYDROXY 6 NITRO 1H BENZOIMIDAZOL 2 YL)PHENYL] 3 (4 METHOXYPHENYL)ACRYLAMIDE; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR LCRF; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL VIRULENCE; CELL FREE SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; IC 50; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TYPE III SECRETION SYSTEM; YERSINIA INFECTION; YERSINIA PESTIS; YERSINIA PSEUDOTUBERCULOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BENZIMIDAZOLES; CELL LINE; CELL-FREE SYSTEM; DNA; DRUG DISCOVERY; INHIBITORY CONCENTRATION 50; MICE; PLAGUE; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATORS; VIRULENCE; YERSINIA PESTIS; YERSINIA PSEUDOTUBERCULOSIS;

EID: 70349197665     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9006577     Document Type: Article

References (41)

1. Perry, R. D.; Fetherston, J. D. Yersinia pestis-etiologic agent of plague. Clin. Microbiol. Rev. 1997, 10, 35-66.
2. Hawley, R. J.; Eitzen, E. M. Biological weapons-a primer for microbiologists. Annu. Rev. Microbiol. 2001, 55, 235-253.
3. Welch, T. J.; Fricke, W. F.; McDermott, P. F.; White, D. G.; Rosso, M.-L.; Rasko, D. A.; Mammal, M. K.; Eppinger, M.; Rosovitz, M. J.; Wagner, D.; Rahalison, L.; LeClerc, J. E.; Hinshaw, J. M.; Lindler, L. E.; Cebula, T. A.; Carniel, E.; Ravel, J. Multiple antimicrobial resistance in plague: an emerging public health risk. PLoS ONE 2007, 2, e309.
4. Levy, S. B. Antibiotic resistance-the problem intensifies. Adv. Drug. Delivery Rev. 2005, 57, 1446-1450.
5. Talbot, G. H.; Bradley, J.; Edwards, J. E., Jr.; Gilbert, D.; Scheld, M.; Bartlett, J. G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Disease Society of America. Clin. Infect. Dis. 2006, 42, 657-668.
6. Projan, S. J.; Bradford, P. A. Late stage antibacterial drugs in the clinical pipeline. Curr. Opin. Microbiol. 2007, 10, 441-446.
7. Clatworthy, A. E.; Pierson, E.; Hung, D. T. Targeting virulence: a new paradigm for antimicrobial therapy. Nat. Chem. Biol. 2007, 3, 541-548.
8. Alekshun, M. N.; Levy, S. B. Targeting virulence to prevent infection: to kill or not to kill? Drug Discovery Today: Ther. Strategies 2004, 1, 483-489.
9. Alksne, L. E.; Projan, S. J. Bacterial virulence as a target for antimicrobial chemotherapy. Curr. Opin. Biotechnol. 2000, 11, 625-636.
10. Bowser, T. E.; Bartlett, V. J.; Grier, M. C.; Verma, A. K.; Warchol, T.; Levy, S. B.; Alekshun, M. N. Novel anti-infection agents: small-molecule inhibitors of bacterial transcription factors. Bioorg. Med. Chem. Lett. 2007, 17, 5652-5655.
11. Multiple adaptational response (MAR) proteins are defined as a subgroup of the AraC family transcription factors that control the virulence of bacteria. A subset of MAR proteins may also control antibiotic resistance (see ref 12).
12. Seoane, A. S.; Levy, S. B. Characterization of MarR, the repressor of the multiple antibiotic resistance (mar) operon in Escherichia coli. J. Bacteriol. 1995, 177, 3414-3419.
13. Casaz, P.; Garrity-Ryan, L. K.; McKenney, D.; Jackson, C.; Levy, S. B.; Tanaka, S. K.; Alekshun, M. N. MarA, SoxS and Rob function as virulence factors in an Escherichia coli murine model of ascending pyelonephritis. Microbiology 2006, 152, 3643-3650.
14. Egan, S. M. Growing repertoire of AraC/XylS activators. J. Bacteriol. 2002, 184, 5529-5532.
15. Gallegos, M.; Schleif, R.; Bairoch, A.; Hofmann, K.; Ramos, J. AraC/XylS family of transcriptional regulators. Microbiol. Mol. Biol. Rev. 1997, 61, 393-410.
16. Flashner, Y.; Mamroud, E.; Tidhar, A.; Ber, R.; Aftalion, M.; Gur, D.; Lazar, S.; Zvi, A.; Bino, T.; Ariel, N.; Velan, B.; Shafferman, A.; Cohen, S. Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates. Infect. Immun. 2004, 72, 908-915.
17. Champion, G. A.; Neely, M. N.; Brennan, M. A.; DiRita, V. J. A branch in the ToxR regulatory cascade of Vibrio cholerae revealed by characterization of toxT mutant strains. Mol. Microbiol. 1997, 23, 323-331.
18. Bieber, D.; Ramer, S. W.; Wu, C. Y.; Murray, W. J.; Tobe, T.; Fernandez, R.; Schoolnik, G. K. Type IV pili, transient bacterial aggregates, and virulence of enteropathogenic Escherichia coli. Science 1998, 280, 2114-2118. (Pubitemid 28366204)
19. Hoe, N. P.; Minion, F. C.; Goguen, J. D. Temperature sensing in Yersinia pestis: regulation of yopE transcription by lcrF. J. Bacteriol. 1992, 174, 4275-4286.
20. Mota, L. J.; Cornelis, G. R. The bacterial injection kit: type III secretion systems. Ann. Med. 2005, 37, 234-249.
21. Cornelis, G. R.; Wolf-Watz, H. The Yersinia Yop virulon: a bacterial system for subverting eukaryotic cells. Mol. Microbiol. 1997, 23, 861-867.
22. Logsdon, L. K.; Mecsas, J. Requirement of the Yersinia pseudotuberculosis effectors YopH and YopE in colonization and persistence in intestinal and lymph tissues. Infect. Immun. 2003, 71, 4595-4607.
23. Mecsas, J.; Bilis, I.; Falkow, S. Identification of attenuated Yersinia pseudotuberculosis strains and characterization of an orogastric infection in BALB/c mice on day 5 postinfection by signature-tagged mutagenesis. Infect. Immun. 2001, 69, 2779-2787.
24. Monack, D. M.; Mecsas, J.; Bouley, D.; Falkow, S. Yersinia-induced apoptosis in vivo aids in the establishment of a systemic infection of mice. J. Exp. Med. 1998, 188, 2127-2137.
25. Garrity-Ryan, L. K.; Kim, O. K.; Balada-Llasat, J.-M.; Bartlett, V. J.; Verma, A. K.; Fisher, M. L.; Castillo, C.; Songsungthong, W.; Tanaka, S. K.; Levy, S. B.; Mecsas, J.; Alekshun, M. N. Unpublished results: in our own experiment, deletion of the lcrF gene exhibited a similar effect of attenuating virulence of Y. pseudotuberculosis.
26. Nordfelth, R.; Kauppi, A. M.; Norberg, H. A.; Wolf-Watz, H.; Elofsson, M. Small-molecule inhibitors specifically targeting type III secretion. Infect. Immun. 2005, 73, 3104-3114.
27. Kauppi, A. M.; Nordfelth, R.; Uvell, H.; Wolf-Watz, H.; Elofsson, M. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem. Biol. 2003, 10, 241-249.
28. Pan, N. J.; Brady, M. J.; Leong, J. M.; Goguen, J. D. Targeting type III secretion in Yersinia pestis. Antimicrob. Agents Chemother. 2009, 53, 385-392.
29. Of all peer-reviewed articles searched through SciFinder and Google Scholar, Elofsson et al. suggested that select small molecule inhibitors of T3SS in Yersinia might directly interact with LcrF. However, based on the experimental data, they either ruled out the possibility, or concluded it was unknown (see refs 26 and 27).
30. Kwon, H. J.; Bennik, M. H. J.; Demple, B.; Ellenberger, T. Crystal structure of the Escherichia coli Rob transcription factor in complex with DNA. Nat. Struct. Biol. 2000, 7, 424-430.
31. Rhee, S.; Martin, R. G.; Rosner, J. L.; Davies, D. R. A novel DNA-binding motif in MarA: The first structure for an AraC family transcriptional activator. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 10413-10418.
32. Proteins were aligned using the BLASTp program on the National Center for Biotechnology Information (NCBI) Web site: http://www.ncbi.nlm.nih.gov
33. Gardiner, J. M.; Procter, J. Synthesis of N-alkoxybenzimidazoles with differentiated C2 and O-substituents. Tetrahedron Lett. 2001, 42, 5109-5111.
34. DeStevens, G.; Brown, A. B.; Rose, D.; Chernov, H. I.; Plummer, A. J. Derivatives of 1-hydroxybenzimidazoles and 1-hydroxyindoles and their central depressant effects. J. Med. Chem. 1967, 10, 211-214.
35. Wermuth, C. G. Molecular variations based on isosteric replacements. In The Practice of Medicinal Chemistry; Wermuth, C. G. Ed.; Academic Press Limited: London, 1996; pp 203-247.
36. Ohmori, J.; Sakamoto, S.; Kubota, H.; Shimizu-Sasamata, M.; Okada, M.; Kawasaki, S.; Hidaka, K.; Togami, J.; Furuya, T.; Murase, K. 6-(l H-imidazol-l-y1)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: Structure-activity relationships for the AMPA-type non-NMDA receptor. J. Med. Chem. 1994, 37, 467-475.
37. In the whole cell cytotoxicity assay, Y. pseudotuberculosis was used instead of Y. pestis in order to address biosafety concerns associated with Y. pestis (category A pathogen). The chromosomes of Y. pestis and Y. pseudotuberculosis are highly similar, and these two pathogens possess a common set of virulence factors including LcrF (see ref 38).
38. Achtman, M.; Zurth, K.; Morelli, G.; Torrea, G.; Guiyoule, A.; Carniel, E. Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 14043-14048.
39. Ellison, D. W.; Miller, V. L. Regulation of virulence by members of the MarR/SlyA family. Curr. Opin. Microbiol. 2006, 9, 153-159.
40. Hong, M.; Fuangthong, M.; Helmann, J. D.; Brennan, R. G. Structure of an OhrR-ohrA operator complex reveals the DNA binding mechanism of the MarR family. Mol. Cell 2005, 20, 131-141.
41. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard, M07-A7, 7th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, 2006.